Redx to present new scientific data at ESMO 2017

RNS Number : 4130P

Redx Pharma plc

31 August 2017

 

31 August 2017

REDX PHARMA PLC (in administration)

("Redx" or "the Company")

Redx to present new scientific data at ESMO 2017

Redx Pharma will present a poster on their planned first-in-human clinical trial for RXC004 at the European Society for Medical Oncology (ESMO) Annual Meeting, September 8-12, 2017, in Madrid.

Session Date & Time	September 9, 2017, 13:15 AM -14:15 GMT+1h
Session Title	GASTROINTESTINAL TUMOURS, COLORECTAL
Presentation Title	Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening
Session Location	Hall 8
Abstract #	692P
First author	Matilda Bingham
Abstract online	https://cslide.ctimeetingtech.com/library/esmo/browse/search/2iw4#2Bb5o02mE

Iain Ross, Chairman, commented:

'We're delighted to present new scientific data on our most advanced program, the Porcupine inhibitor RXC004 as it moves closer to the clinic. We have a strong portfolio of research assets and continue to look for novel opportunities in several therapeutic classes in oncology and immunology.'

For further information, please contact:

Redx Pharma Plc (in administration)
Contact for the Joint Administrators: Chris French James Rossiter	T: + 44 203 005 4000
Cantor Fitzgerald Europe (Nomad & Broker)	T: [phone]
Phil Davies
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson

About Redx Pharma Plc (in administration)

Company website: redxpharma.com

Jason Baker and Miles Needham have been appointed as joint administrators of Redx Pharma plc (in administration). The company's affairs, business and property are being managed by the joint administrators.

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 

END

 

 

NRASDWSWFFWSEIA